Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$85.04

-1.83 (-2.11%)

, PTCT

PTC Therapeutics

$13.27

-0.3 (-2.21%)

09:08
10/17/16
10/17
09:08
10/17/16
09:08

PTC's denial has negative read-through for BioMarin, says Janney Capital

Janney Capital noted that PTC Therapeutics' (PTCT) Translarna and Sarepta's (SRPT) Exondys 51 address non-overlapping DMD populations and there was an expectation of flexibility from the FDA following the conditional approval of Exondys 51. However, the FDA has denied the first appeal of the refuse to file letter regarding PTC's NDA for Translarna for the treatment of nonsense mutation DMD, which the firm said has potential negative read-through for BioMarin's (BMRN) attempt to rekindle Kyndrisa, which is a direct competitor to Sarepta's Exondys 51. The firm added that the news might positively impact reimbursement decisions for Exondys 51.

BMRN

BioMarin

$85.04

-1.83 (-2.11%)

PTCT

PTC Therapeutics

$13.27

-0.3 (-2.21%)

SRPT

Sarepta

$52.28

-1.91 (-3.52%)

  • 27

    Oct

  • 06

    Nov

  • 29

    Nov

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

BMRN BioMarin
$85.04

-1.83 (-2.11%)

09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/14/16
BARD
10/14/16
NO CHANGE
Target $115
BARD
Outperform
BioMarin hemophilia drug update encouraging, says Baird
Baird analyst Michale Ulz said he is encouraged by BioMarin's update on its Phase 1/2 study of its Hemophilia A drug, BMN-270. The analyst noted U.K. regulators approved continued enrollment in the gene-therapy study and the study was amended to allow dose optimization ahead of the Phase 2b study expected in 2017. Ulz reiterated his Outperform rating and $115 price target on BioMarin shares.
PTCT PTC Therapeutics
$13.27

-0.3 (-2.21%)

07/20/16
WEDB
07/20/16
NO CHANGE
Target $12
WEDB
Neutral
Wedbush staying on sidelines on PTC Therapeutics after NICE issues guidance
Noting that NICE has finalized access for England for PTC Therapeutics' Translarna, Wedbush analyst Heather Behanna said she remains on the sidelines on PTC shares, citing the drug's continued regulatory and pricing risks in Europe. While keeping a Neutral rating and $12 price target on PTC shares, Behanna said she believes it is unlikely that the EMA will pull the drug from the market and sees "meaningful upside" in early 2017 if Translarna can demonstrate a statistically significant positive result in cystic fibrosis.
10/03/16
BOFA
10/03/16
NO CHANGE
Target $15
BOFA
Buy
PTC Therapeutics price target raised to $15 from $9 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised PTC Therapeutics' price target to $15 from $9 following partner Roche's recruitment for a trial it is conducting to investigate a potential treatment for Spinal Muscular Atrophy, or SMA, patients. Given this advancement, the analyst is raising his probability of approval to 30% from 20% in SMA and maintains his Neutral rating.
09/20/16
JEFF
09/20/16
NO CHANGE
Target $7
JEFF
Hold
Jefferies thinks eteplirsen approval will have limited impact on PTC
Jefferies analyst Gena Wang believes yesterday's FDA approval of Sarepta Therapeutics' (SRPT) eteplirsen will have a limited impact on PTC Therapeutics (PTCT). While PTC's potential treatment for Duchenne muscular dystrophy ataluren is considered safe, the FDA approval of eteplirsen is mainly based on the marginal increase of dystrophin level and PTC does not have any dystrophin data from Phase 3, Wang tells investors in a research note. Eteplirsen's approval could pressure the FDA to reconsider the review progress of ataluren, but the final outcome would likely remain the same, the analyst contends. She keeps a Hold rating on PTC with a $7 price target. The stock closed yesterday up 21%, or $1.88, to $10.99.
07/26/16
FBCO
07/26/16
DOWNGRADE
Target $6
FBCO
Neutral
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Alethia Young downgraded PTC Therapeutics to Neutral and lowered its price target to $6 from $12 citing further uncertainty around the Eurozone DMD approval case. Following the company's release, Young believes that the approval timelines in EU at the best case are now longer than his original expectations though the drug does remain on the market and lowered his probability of success in EMA to 75% from $100.
SRPT Sarepta
$52.28

-1.91 (-3.52%)

10/07/16
BARD
10/07/16
NO CHANGE
Target $102
BARD
Outperform
Anthem policy does not mean insurer not covering Sarepta drug, says Baird
Baird analyst Brian Skorney noted Anthem (ANTM) has categorized Sarepta (SRPT) Duchenne muscular dystrophy drug Exondys 51 as "not medically necessary" in a new coverage policy, but he cautions this "does not mean that Anthem is not covering the drug." The analyst explains that the policy means prior authorization requirements may be stricter, but he "highly doubts" that eligible patients will be denied coverage. Skorney, who adds that other large insurers appear to have favorable coverage for the drug, keeps an Outperform rating and $102 price target on Sarepta shares.
10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

ACN

Accenture

$121.23

0.51 (0.42%)

15:17
02/20/17
02/20
15:17
02/20/17
15:17
Hot Stocks
Accenture announces intent to acquire SinnerSchrader »

Accenture announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGG

CGG SA

15:13
02/20/17
02/20
15:13
02/20/17
15:13
Hot Stocks
CGG SA says secures consent from debt holders »

CGG SA CGG announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PI

Impinj

$31.17

-4.19 (-11.85%)

15:05
02/20/17
02/20
15:05
02/20/17
15:05
Hot Stocks
Impinj announces partnership, platform integration with STANLEY Healthcare »

Impinj announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

HRS

Harris

$109.46

0.81 (0.75%)

15:03
02/20/17
02/20
15:03
02/20/17
15:03
Hot Stocks
Harris wins $189M contract with UAE military »

Harris has received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$100.52

-0.3 (-0.30%)

15:01
02/20/17
02/20
15:01
02/20/17
15:01
Hot Stocks
Alibaba announces strategic partnership with Bailian Group »

Alibaba and Chinese…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 19

    Mar

SWIR

Sierra Wireless

$27.80

1.575 (6.01%)

, VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

14:58
02/20/17
02/20
14:58
02/20/17
14:58
Hot Stocks
Sierra Wireless says connected car products selected by Volkswagen »

Sierra Wireless (SWIR)…

SWIR

Sierra Wireless

$27.80

1.575 (6.01%)

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNX

Progenics

$10.62

0.08 (0.76%)

, CLMS

Calamos

$8.24

-0.03 (-0.36%)

14:55
02/20/17
02/20
14:55
02/20/17
14:55
Hot Stocks
Progenics to replace Calamos in S&P 600 as of 2/20 close »

Calamos Asset Management…

PGNX

Progenics

$10.62

0.08 (0.76%)

CLMS

Calamos

$8.24

-0.03 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 01

    Mar

SFLY

Shutterfly

$48.06

0.66 (1.39%)

, VASC

Vascular Solutions

14:55
02/20/17
02/20
14:55
02/20/17
14:55
Hot Stocks
Shutterfly to replace Vascular Solutions in S&P 600 as of 2/20 close »

S&P MidCap 400…

SFLY

Shutterfly

$48.06

0.66 (1.39%)

VASC

Vascular Solutions

TFX

Teleflex

$179.91

1.86 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NKTR

Nektar

$13.10

0.12 (0.92%)

, BMY

Bristol-Myers

$54.59

0.31 (0.57%)

14:48
02/20/17
02/20
14:48
02/20/17
14:48
Hot Stocks
Nektar reports Phase 1 data on NKTR-214 in kidney cancer »

Nektar Therapeutics…

NKTR

Nektar

$13.10

0.12 (0.92%)

BMY

Bristol-Myers

$54.59

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

XNCR

Xencor

$24.28

0.5 (2.10%)

14:38
02/20/17
02/20
14:38
02/20/17
14:38
Hot Stocks
Xencor announces data presentation on XmAb5871 »

Xencor announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

RHHBY

Roche

$30.53

0.02 (0.07%)

14:35
02/20/17
02/20
14:35
02/20/17
14:35
Hot Stocks
Genentech reports Phase 2 data on Tecentriq combo in kidney cancer »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 09

    Mar

  • 26

    Jun

RVSB

Riverview Bancorp

$7.50

-0.11 (-1.45%)

14:30
02/20/17
02/20
14:30
02/20/17
14:30
Hot Stocks
Breaking Hot Stocks news story on Riverview Bancorp »

Riverview Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCN

Ocwen

$5.24

0.09 (1.75%)

14:27
02/20/17
02/20
14:27
02/20/17
14:27
Hot Stocks
Ocwen reaches settlement, termination of California consent order »

Ocwen Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SYF

Synchrony

$36.68

-0.17 (-0.46%)

14:07
02/20/17
02/20
14:07
02/20/17
14:07
Periodicals
Synchrony likely to see more gains, Barron's says »

Synchrony "still has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANTM

Anthem

$160.25

-3.52 (-2.15%)

, CI

Cigna

$143.56

-1.77 (-1.22%)

14:05
02/20/17
02/20
14:05
02/20/17
14:05
Periodicals
Merger collapse could get Anthem back on track, Barron's says »

The likely collapse of…

ANTM

Anthem

$160.25

-3.52 (-2.15%)

CI

Cigna

$143.56

-1.77 (-1.22%)

ESRX

Express Scripts

$69.97

0.74 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

QSR

Restaurant Brands

$53.90

0.05 (0.09%)

, PLKI

Popeyes

$66.12

-0.26 (-0.39%)

13:50
02/20/17
02/20
13:50
02/20/17
13:50
Periodicals
Restaurant Brands in advanced talks to buy Popeyes, Bloomberg says »

A deal could be announced…

QSR

Restaurant Brands

$53.90

0.05 (0.09%)

PLKI

Popeyes

$66.12

-0.26 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

AAPL

Apple

$135.72

0.375 (0.28%)

, AMAT

Applied Materials

$35.67

0.49 (1.39%)

13:48
02/20/17
02/20
13:48
02/20/17
13:48
Periodicals
Smartphone design trends could benefit Applied Materials, others, Barron's says »

As Apple (AAPL) and other…

AAPL

Apple

$135.72

0.375 (0.28%)

AMAT

Applied Materials

$35.67

0.49 (1.39%)

OLED

Universal Display

$72.15

0.85 (1.19%)

GLW

Corning

$27.65

-0.06 (-0.22%)

SSNLF

Samsung

LPL

LG Display

$12.39

0.07 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 13

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

  • 28

    Mar

  • 01

    Apr

TOSBF

Toshiba, also use TOSYY

$1.61

-0.182 (-10.17%)

, TOSYY

Toshiba, also use TOSBF

$9.55

-1.085 (-10.21%)

13:32
02/20/17
02/20
13:32
02/20/17
13:32
Periodicals
Toshiba could have 50% upside, Barron's says »

Toshiba shares are…

TOSBF

Toshiba, also use TOSYY

$1.61

-0.182 (-10.17%)

TOSYY

Toshiba, also use TOSBF

$9.55

-1.085 (-10.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIN

DineEquity

$60.14

-6.41 (-9.63%)

13:27
02/20/17
02/20
13:27
02/20/17
13:27
Periodicals
DineEquity remains challenged, Barron's says »

"Problems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

HD

Home Depot

$143.00

1.46 (1.03%)

13:09
02/20/17
02/20
13:09
02/20/17
13:09
Periodicals
Home Depot looks healthy into earnings report, Barron's says »

Home Depot remains the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 15

    Mar

ADNT

Adient

$64.01

-0.69 (-1.07%)

, JCI

Johnson Controls

$41.91

0.23 (0.55%)

12:58
02/20/17
02/20
12:58
02/20/17
12:58
Periodicals
Adient could offer 35% upside, Barron's says »

Shares of Adient (ADNT)…

ADNT

Adient

$64.01

-0.69 (-1.07%)

JCI

Johnson Controls

$41.91

0.23 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$51.75

0.45 (0.88%)

12:47
02/20/17
02/20
12:47
02/20/17
12:47
Periodicals
Steer clear of Hess Corp, Barron's says »

Hess Corp shares are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

GM

General Motors

$37.22

0.19 (0.51%)

12:33
02/20/17
02/20
12:33
02/20/17
12:33
Periodicals
General Motors stock could reach $50 in a year, Barron's says »

Shares of General Motors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

11:43
02/20/17
02/20
11:43
02/20/17
11:43
Conference/Events
DA Davidson E&C and industrials analysts hold analyst/industry conference call »

E&C, Materials &…

11:38
02/20/17
02/20
11:38
02/20/17
11:38
Conference/Events
DA Davidson technology/software analysts hold analyst/industry conference call »

Technology Analyst…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.